2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.26 A Multicenter Retrospective Study Reveals High MET Expression Associated with Superior Benefit from Immunotherapy in Advanced NSCLC Patients

P4.11E.26 A Multicenter Retrospective Study Reveals High MET Expression Associated with Superior Benefit from Immunotherapy in Advanced NSCLC Patients

Back to course

Pdf Summary

The multicenter retrospective study, conducted by a team including Hui Li and colleagues from various global institutions, investigates the relationship between MET protein expression and response to immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients. The study included 428 stage IV NSCLC patients from three cancer centers: MD Anderson Cancer Center (USA), Hospital del Mar (Spain), and Zhejiang Cancer Hospital (China). Among these patients, 382 received ICIs while 46 underwent chemotherapy alone.<br /><br />Using immunohistochemistry (IHC), MET expression was graded from 0 to 3, with 2 and 3 indicating high expression. Analysis of overall survival (OS) and progression-free survival (PFS) was conducted using Kaplan-Meier and Cox proportional hazards models. The results revealed that high MET expression correlates with improved overall survival in NSCLC patients treated with ICIs, independent of PD-L1 expression levels. However, this correlation was not observed in the chemotherapy-alone cohort.<br /><br />Further, stratifying by PD-L1 and MET expressions, it was found that high expressions of both were linked to superior outcomes. The study also included a subgroup analysis focusing on patients biopsied before ICI treatment, which indicated that high MET expression was significantly associated with better OS.<br /><br />Overall, the study suggests that high MET expression can serve as an independent predictor of better response to ICIs in advanced NSCLC, providing a potential biomarker for treatment stratification. This insight could lead to more personalized approaches in immunotherapy for NSCLC patients. The study’s findings were supported by literature emphasizing the biological role of MET in cancer resistance and progression. References indicate a growing body of work examining the role of MET as a promising target and biomarker across different cancer treatments.

Asset Subtitle

Hui Li

Meta Tag

Speaker Hui Li

Topic Metastatic NSCLC – Immunotherapy

Keywords

MET protein expression

immune checkpoint inhibitors

non-small cell lung cancer

NSCLC

immunohistochemistry

overall survival

progression-free survival

PD-L1 expression

biomarker

personalized immunotherapy